Wuxi Jesse Pharmaceutical

Wuxi Jesse Pharmaceutical is a clinical-stage biotechnology company based in Wuxi, China, specializing in the development of innovative drugs derived from natural products and small molecules. Founded in 2002 by Dr. Cheng Jingcai, the company focuses on chronic inflammatory diseases, cardiovascular conditions, and oncology. Its lead program, NTI-528, is an oral aryl hydrocarbon receptor (AhR) modulator in Phase 2 development for inflammatory bowel disease and psoriasis. Another key candidate, JC-5411 (phenethyl isothiocyanate), is being evaluated in Phase 2 trials for benign prostatic hyperplasia and advanced prostate cancer. The company leverages its expertise in natural product chemistry and GMP manufacturing to advance a pipeline of first-in-class and best-in-class treatments. Wuxi Jesse has established several research centers, including the Guo Yinglu Academician Workstation, to support its R&D efforts.